Skip To Main Content
Vacis Tatarunas on Muck Rack

Vacis Tatarunas

As seen in: MDPI, Future Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vacis

Contact Vacis, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Enterobacterales Biofilm-Specific Genes and Antimicrobial and Anti-Inflammatory Biomarkers in the Blood of Patients with Ischemic Heart Disease

|
By Agne Giedraitiene, Vacis Tatarunas, Kornelija Kaminskaite, Ugne Meskauskaite
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared Issue with article?

Blood direct PCR: impact of CYP2C19 and CYP4F2 variants for bleeding prediction in ST-elevation myocardial infarction patients with ticagrelor

|
By Vacis Tatarunas, Ali Aldujeli, Zemyna Kurnickaite, Laurynas Maciulevicius
| Future Medicine Verified
Today ticagrelor is one of the main antiplatelet drugs in preventing secondary events after percutaneous coronary intervention (PCI). Current guidelines of the European Society of Cardiology recommend dual antiplatelet therapy (DAPT) with ticagrelor and aspirin over clopidogrel and aspirin DAPT [1]. Compared with clopidogrel, ticagrelor is a newer, third-generation drug.
Open in Who Shared Issue with article?

The impact of CYP2C19 and CYP4F2 variants and clinical factors on treatment outcomes during antiplatelet therapy

|
By Vacis Tatarunas, Nora Kupstyte-Kristapone, Rita Norvilaite, Vytenis Tamakauskas
| Future Medicine Verified
PharmacogenomicsVol. 20, No. 7 Research Article Vacis Tatarunas, Nora Kupstyte-Kristapone, Rita Norvilaite, Vytenis Tamakauskas, Vilius Skipskis, Veikutiene Audrone, Julija Jurgaityte, Mantvydas Stuoka & Vaiva Lesauskaite Abstract Aim: The aim of this study was to determine the impact of genetic and nongenetic factors on treatment outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention and stent implantation.
Open in Who Shared Issue with article?
See all 4 articles